Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|September 2, 2026

Viral Vector Quality: No Estimates. Only Evidence

Listen
0:00 / 0:00

Key Takeaways

  • Viral titer alone can mask clinically relevant differences in empty/full ratios, fragmented genomes, and higher-order aggregates that influence potency, safety, and regulatory defensibility.
  • Charge detection mass spectrometry provides direct capsid mass distributions, enabling streamlined characterization and relative quantitation of AAV subpopulations across development and QC workflows.
SHOW MORE

Move beyond inferred measurements and gain direct insight into the viral vector quality attributes that drive efficacy, safety, and manufacturing confidence.

AAV quality depends on more than viral titer alone. Capsid occupancy, aggregation, genome integrity, and product heterogeneity all impact therapeutic performance and regulatory readiness. Explore how CDMS and MALS help scientists generate direct, defensible evidence to support development, manufacturing, and QC decisions.

Characterizing AAVs


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.